Lupus & antiphospholipid syndrome

Association of Hydroxychloroquine Dose With Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus

Arthritis Care Res (Hoboken)Published Retrospective cohort study

Authors' conclusion

Higher HCQ doses were not associated with an increased risk of HFrEF, life-threatening arrhythmia, or cardiac death among patients with SLE and may decrease the risk among nonsmokers.

Study context

Population
Patients with systemic lupus erythematosus (SLE) taking hydroxychloroquine (HCQ) with ≥1 echocardiogram, tertiary care center in the Bronx, New York, 2005–2021median follow-up 7.9 years
Participants
294 patients
Exposure
HCQ weight-based dose at HCQ start, stratified by smoking status
  • Nonsmokersn = 226
  • Smokersn = 68
Outcome
Incident all-cause heart failure with reduced ejection fraction (HFrEF), life-threatening arrhythmia, or cardiac death
Methodological detailssingle tertiary care centre, Fine-Gray regression with death as competing event, stratified by smoking status, propensity score analysis (secondary)
  • Single tertiary care centre
  • Fine-Gray regression with death as competing event
  • Stratified by smoking status
  • Propensity score analysis (secondary)

Main finding

As reported in the abstract

HFrEF, life-threatening arrhythmia or cardiac death, per higher HCQ weight-based dose
Estimate (CI)P value
Nonsmokersinterval printed as IQR; adjusted for age, BMI, hypertension, CKD, diabetes mellitus, thromboembolism
subdistribution HR 0.62(0.41–0.92)
P = 0.02
Smokersinterval printed as IQR
subdistribution HR 0.85 per mg/kg(0.53–1.34)
P = 0.48

Each row per its own increment, as printed

Developed the outcome (all patients)
37 (13%)

Observational data: associations, not effects.

Further findings

Propensity score analysis (secondary analysis)

Propensity score analysis showed comparable results

Original publication

Association of Hydroxychloroquine Dose With Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). Published 3 February 2023. doi:10.1002/acr.25052

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.